Cadila Pharmaceuticals Ltd.

This June, CPL, a leader in the development and manufacturing of liquids and semisolids, will arrive at CPHI Americas in Philadelphia with more than just their team members. The event marks one of the first major opportunities for the organization to formally showcase its evolving brand identity, sharpened market focus, and expanding early pharmaceutical development (including its Skin Lab) and commercial manufacturing capabilities to a broad North American audience. As one of the industry’s premier gatherings for pharmaceutical development, manufacturing, supply chain, and outsourcing professionals, CPHI Americas creates an ideal environment for meaningful conversations between innovators, sponsors, CDMOs, and strategic partners. For CPL, the timing could not be better. Over the past several months, CPL has been working to refine how the organization communicates its strengths to the market. This has led to a focus on how CPL differentiates itself in the liquid and semisolid space through partnership, scientific expertise, responsiveness, flexibility, and a highly collaborative approach to drug development and manufacturing support. CPHI Americas provides the perfect venue to bring those conversations to life. CPL’s presence at this year’s conference reflects an organization that is continuing to evolve alongside the pharmaceutical industry itself. As development timelines accelerate and sponsors seek increasingly agile manufacturing and formulation partners, CPL is positioning itself as a company capable of supporting both emerging innovators and established pharmaceutical organizations with tailored solutions and hands-on collaboration. Attendees visiting CPL during the show can expect conversations that go beyond transactional manufacturing discussions. The team is eager to discuss how strategic CDMO partnerships can help sponsors navigate liquid and semisolid formulation challenges, skin testing, scale-up considerations, regulatory expectations, commercialization planning, and speed-to-market pressures in today’s increasingly competitive landscape. That approach aligns closely with the broader themes currently shaping the industry. Sponsors are looking for partners who can move quickly, communicate clearly, and provide integrated expertise across development and manufacturing workflows. CPL’s team understands those demands and has built its services around helping customers solve real-world pharmaceutical challenges with efficiency and technical precision. CPHI Americas brings together exactly the types of audiences CPL is seeking to engage. The event attracts pharmaceutical innovators, biotech startups, virtual pharma organizations, formulation scientists, procurement leaders, supply chain professionals, and outsourcing decision-makers from across North America and beyond. For CPL, the conference creates an opportunity to highlight the breadth of its pharmaceutical capabilities while also demonstrating the culture and responsiveness that define the company’s client relationships. The organization is especially looking forward to discussing areas where pharmaceutical companies continue to face mounting pressure, including: Accelerating development timelines for oral liquids, nasal sprays and topicals Scaling formulations efficiently Navigating manufacturing complexity Managing supply chain uncertainty Identifying responsive long-term CDMO partners Supporting specialized dosage forms and complex formulations These conversations have become increasingly important throughout the pharmaceutical industry, particularly as companies seek development and manufacturing partners capable of adapting quickly to changing market conditions and evolving therapeutic demands. More than anything, CPL is looking forward to connecting with organizations seeking genuine collaboration rather than simple vendor relationships. The most valuable conversations at CPHI Americas are often the ones centered around long-term strategy, future product pipelines, formulation hurdles, commercialization goals, and operational scalability. CPL’s team welcomes those discussions and sees them as an opportunity to better understand how pharmaceutical companies are adapting to the current market environment. Whether attendees are exploring new development partnerships, evaluating manufacturing support, seeking formulation expertise, or simply looking to better understand CPL’s expanding capabilities, the organization encourages visitors to stop by and engage with the team during the event. CPHI has always been about relationship-building as much as business development, and CPL is approaching this year’s conference with that same mindset. As CPL continues to introduce its refreshed brand identity to the broader pharmaceutical industry, CPHI Americas represents an exciting milestone for the organization and its future growth initiatives. In addition to meeting with attendees throughout the conference, CPL will also be hosting an exclusive happy hour event during the show. For more information about the event, attendees are encouraged to reach out directly to a member of the CPL team. The organization looks forward to reconnecting with existing partners, meeting new industry contacts, and continuing conversations that help drive pharmaceutical innovation forward. If you will be attending CPHI Americas 2026 in Philadelphia, be sure to connect with CPL and learn more about how the organization is helping pharmaceutical companies navigate development and manufacturing liquids and semisolids with confidence, flexibility, and partnership-driven support.

周五，国家局发文，暂停进口、销售、使用Cadila Pharmaceuticals公司的苯磺酸氨氯地平原料药。 原因是，国家局在现场检查时发现，产品部分工序实际生产地址与注册信息不一致，生产过程中还存在多项变更未按要求及时申报、实际生产工艺与批准工艺不一致等情况，不符合我国《药品生产质量管理规范（2010年修订）》及附录有关要求。 因此，暂停产品进口，原料药登记状态转为I（即未通过与制剂共同审评审批），此原料药不得用于制剂生产，已生产的制剂不得方兴，已上市放行的制剂，持有人需要采取必要的风控措施。 这几年，国采以及接续等，使得氨氯地平相关产品的价格非常低，企业都在千方百计降成本，找便宜的原料药，就是省钱之道。 但是，一味的追求便宜，潜在的风险就会增加。 就拿这次来说，如果有企业，用了Cadila的原料，就不得不另外更换原料药，这就需要做变更申报，还要重新备案，耽误时间，很有可能会导致暂时停产，无法及时供货。 对于国采接续的品种来说，只要企业无法及时供货，已有市场就会拱手让人，甚至还有可能记入招采信用黑名单啊。 找一个稳定可靠的供应商，真的很重要啊。 用摩熵药筛小程序，查询国采接续中选价格！ 国采续采交流群已建，加客服微信，入群交流！

转自：国家药监局 编辑：水晶 2026年4月3日，国家药品监督管理局发布公告，宣布即日起暂停进口、销售和使用印度Cadila Pharmaceuticals Limited公司生产的苯磺酸氨氯地平原料药。 此次决定源于国家药监局近期对该原料药进行的现场检查。检查的问题： 生产地址不一致：部分生产工序的实际地址与注册信息不符。 变更未申报：生产过程中发生多项变更，但未按要求及时向监管部门申报。 工艺不一致：实际生产工艺与获批工艺存在差异。 处罚： 暂停进口：各口岸药监部门暂停发放该原料药的进口通关单。 调整审评状态：该原料药在药审中心的审评审批结果被调整为“I”，即未通过与制剂的共同审评审批。 暂停销售与使用：禁止在境内销售和使用该原料药。药品上市许可持有人需立即对已上市的相关制剂进行调查评估，并采取必要的风险控制措施。 值得注意的是，此前在3月24日，国家药监局已暂停了Vasudha Pharma Chem Limited的盐酸洛哌丁胺原料药，以及Alchem International Private Limited的利血平、地高辛原料药的进口。详见：多个进口原料药被暂停使用→ 近期，国家药监局组织对Cadila Pharmaceuticals Limited苯磺酸氨氯地平原料药（登记号：Y20190009999；生产地址：294，GIDC ESTATE,ANKLESHWAR,GUJARAT STATE,INDIA）开展现场检查。 经查，上述产品部分工序实际生产地址与注册信息不一致，生产过程中还存在多项变更未按要求及时申报、实际生产工艺与批准工艺不一致等情况，不符合我国《药品生产质量管理规范（2010年修订）》及附录有关要求。 根据《中华人民共和国药品管理法》第九十九条、《药品医疗器械境外检查管理规定》第三十条等有关规定，国家药监局决定，自即日起： 一、暂停进口上述原料药，各口岸药品监督管理部门暂停发放该原料药产品的进口通关单。 二、上述原料药在国家药监局药品审评中心“原辅包登记信息”中“与制剂共同审评审批结果”调整为“I”（即未通过与制剂共同审评审批）。 三、上述原料药不得在境内销售、不得用于药品制剂生产，对已使用上述原料药生产的制剂不得放行；已上市放行的制剂，药品上市许可持有人应当立即开展调查与评估，并根据评估结果采取必要的风险控制措施。 特此公告。 国家药监局 2026年3月30日